行情

CORV

CORV

Correvio Pharma Corp
NASDAQ

实时行情|Nasdaq Last Sale

1.980
-0.010
-0.50%
交易中 12:31 10/22 EDT
开盘
1.980
昨收
1.990
最高
1.980
最低
1.980
成交量
2,954
成交额
--
52周最高
4.440
52周最低
1.430
市值
1.00亿
市盈率(TTM)
-2.2675
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CORV 新闻

  • 午盘:财报好坏参半 美股维持窄幅震荡
  • 新浪美股.44分钟前
  • 美国财长姆努钦:已告诉FB目前发行Libra还不成熟
  • 新浪美股.1小时前
  • 因对阿根廷看走眼 富兰克林新兴市场基金被晨星降级
  • 新浪美股.1小时前
  • 美联储周二定期回购操作一个月来首次获得超额认购
  • 新浪美股.2小时前

更多

所属板块

制药
+1.18%
制药与医学研究
+1.04%

热门股票

名称
价格
涨跌幅

CORV 简况

Correvio Pharma Corp is a Canada-based specialty pharmaceutical company. It provides brands that meet the needs of acute care physicians and patients. It develops, acquires and commercializes brands for the in-hospital, acute care market segment. The following is its portfolio of approved and marketed brands: Xydalba, for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Brinavess for the conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, as well as Esmocard and Esmocard Lyo, a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Its pipeline of product candidates includes Trevyent, a drug device combination that is designed to deliver treprostinil.
展开

Webull提供Correvio Pharma Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。